Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
E: werner.lanthaler@evotec.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
5,022
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,590.90 | 66.60 | 0.89% |
| CAC 40 | 6,927.12 | 347.83 | -4.78% |
| DAX 40 | 19,789.62 | 852.10 | -4.13% |
| Dow JONES (US) | 37,965.60 | 2,580.33 | -6.36% |
| FTSE 100 | 7,702.08 | 352.90 | -4.38% |
| HKSE | 19,828.30 | 3,021.51 | -13.22% |
| NASDAQ | 15,603.26 | 947.34 | -5.72% |
| Nikkei 225 | 32,959.01 | 1,822.43 | 5.85% |
| NZX 50 Index | 11,908.86 | 132.98 | 1.13% |
| S&P 500 | 5,062.25 | 11.83 | -0.23% |
| S&P/ASX 200 | 7,394.10 | 50.80 | 0.69% |
| SSE Composite Index | 3,096.58 | 0.00 | 0.00% |